Co-founders Parth Chopra and Saloni Paliwal started Early.Fit after their own struggles with weight and metabolic health and the realization that they weren’t alone – nearly 20 crore Indians are living through an invisible metabolic pandemic. Over six years in New York, Parth and Saloni saw GLP-1s change lives – their friends lost weight, found improved heart health, eased joint pain, and reduced fertility issues. Back home, they saw how hard it was to access the same standard of care. India has the world’s largest diabetic population and the second-largest obese population, yet these medicines launched here only in 2025 and before then, Indians were forced to turn to grey market imports to access this life changing innovation in weight care.
Early.Fit was started to change that – by bringing rigorous, responsible GLP-1 care to the people who need it most. What began in New York is now headquartered in Delhi, serving users across all 28 Indian states. Early.Fit runs doctor-led GLP-1 programs using medications like Ozempic and Mounjaro, helping eligible users lose up to 20% of their weight in 3–6 months in a way that’s safe, supervised, and sustainable.
Prior to building Early, Parth was Director at a Venture Capital firm investing in Healthcare and Human Resources in New York, and Saloni was a Senior Product Manager at Amazon, building critical tech that powered Amazon’s 1,00,000+ delivery fleet.
Early.Fit is designed to not only make GLP-1 weight loss safer but also more effective. Their GLP-1 users who use Early’s app see 1.8x higher weight loss and reduced side effects since they exercise more, eat better, and scientifically manage side-effects.
At the heart of Early.Fit’s approach are a few simple but vital principles:
- Safety & Scientific focus: Fulfil all needs of a GLP-1 user as a one-stop-shop, focused on mitigating side effects and comprehensive diagnostics focused on 35+ weight-loss specific blood markers
- Doctor-led and unbiased. Super-specialist endocrinologists conduct detailed monthly consultations to review reports, determine if GLP-1 is appropriate
- Delivered through App. Smart-scale integration, personalized diet plans, calorie tracking, at-home workouts, side effect management and more through Early.Fit’s phone app
- Coaching based. Unlimited 1:1 connects with senior nutrition coaches
- Sustainable. Focus on weaning users off medication safely while maintaining results through behavioural resets.
“We’re not here to hand out GLP-1s like candy. We’re here to prescribe them responsibly, monitor them medically, and make sure the right people benefit from them safely. If your BMI is over 27, you may be eligible.”
– Parth Chopra, CEO at Early.Fit
Early.Fit has seen clients lose an average of about 20% of their body weight which is consistent with global clinical trials around tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy), the key medications which their programmes are centered around. Many users report broader health gains, including improved cardiac markers, reduced joint pain, lower liver fat, and better diabetes control.
Website: www.early.fit
Instagram: https://www.instagram.com/join.earlyfit
